Summary of the Conference Call for Lepu Biopharma (2157.HK) Company Overview - Lepu Biopharma is focused on the development of innovative cancer therapies, particularly in the areas of immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus drugs. The company has a robust pipeline and is expected to enter a period of new drug approvals in the next 3-5 years [1][2]. Key Points R&D Pipeline and Drug Approvals - The company has developed multiple oncology product lines, including: - PD-1 monoclonal antibody, Pralsetinib, and MRG003, which are already on the market. - Six ADC drugs, one oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages. - The overall pipeline is well-structured, indicating a promising future for new drug approvals [1][2]. Financial Performance - The company has achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development (BD) and sales efforts [2]. Competitive Advantages of ADCs 1. **MRG003 (EGFR ADC)**: - Approved for use in late-line nasopharyngeal carcinoma (NPC) in China, showing superior survival benefits and safety compared to competitors. - Actively pursuing broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), with a Phase III trial ongoing for 2L+ HNSCC [2][3]. 2. **MRG004A (TF-ADC)**: - Currently in Phase III trials for late-line pancreatic cancer, demonstrating strong competitive potential [3]. 3. **MRG006A (GPC3 ADC)**: - A first-in-class (FIC) targeting the liver cancer market, with promising results from Phase I trials, and expected to enter Phase III trials in 2026 [3]. 4. **CMG901**: - A global FIC CLDN 18.2 ADC, currently in Phase III trials [3]. 5. **MRG001 (CD20 ADC)**: - Showing potential in diffuse large B-cell lymphoma (DLBCL) [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is in critical registration bridging trials in China. - Recent Phase III data indicates historical best durability in NMIBC, with a G3+ treatment-related adverse event (TRAE) rate of 0, showcasing both efficacy and safety [3]. International Expansion - The company has successfully collaborated on international projects with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3) [3]. Revenue Projections - Revenue forecasts for the company are as follows: - 2025: 880 million CNY - 2026: 1.02 billion CNY - 2027: 1.49 billion CNY - Expected growth rates are 138% in 2025, 16% in 2026, and 47% in 2027, with net profits projected at -20 million CNY in 2025, 10 million CNY in 2026, and 280 million CNY in 2027 [3]. Investment Rating - The company’s ADC pipeline is progressing steadily, and commercial advancements are on track, leading to a "Buy" rating [4]. Risk Factors - Potential risks include: - Delays in clinical progress of innovative drugs. - Subpar clinical data for innovative drugs. - Poor sales performance post-launch of innovative drugs. - Geopolitical risks [4].

Core Viewpoint - The company is entering a new drug approval phase with a well-structured pipeline in oncology, focusing on immunotherapy, ADC targeted therapy, and oncolytic virus drugs, which is expected to yield multiple new drug approvals in the next 3-5 years [1][2]. Pipeline Development - The company has developed multiple oncology products, including two already marketed drugs (PD-1 monoclonal antibody Prutilizumab and MRG003) and has six ADC drugs, one oncolytic virus, and one TCE drug in clinical stages [1]. - MRG003 (EGFR ADC) has been approved for post-line NPC in China, showing superior survival benefits and safety compared to competitors, with ongoing trials for HNSCC and NSCLC [1]. - MRG004A (TF-ADC) for post-line pancreatic cancer is currently in Phase III trials after demonstrating strong competitive advantages in Phase I [2]. - MRG006A (GPC3 ADC) is targeting the liver cancer market, with promising results in Phase I trials and plans to initiate Phase III trials in 2026 [1][2]. Oncolytic Virus Therapy - The company has introduced the oncolytic virus therapy CG0070 for bladder cancer, which is currently undergoing a rolling BLA application with the FDA and is in critical registration bridging trials in China [2]. - CG0070 has shown the best historical durability efficacy data in the NMIBC field, with a G3+TRAE rate of 0, indicating excellent efficacy and safety [2]. Financial Projections - The company is still in the investment phase for innovative drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 138%, 16%, and 47% [2]. - The net profit attributable to the parent company is expected to be -20 million, 10 million, and 280 million yuan for the same years [2]. Investment Recommendation - The company is rated as a "buy" due to the steady progress of its ADC pipeline and successful commercialization efforts [2].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is entering a new drug approval harvest period with a well-structured pipeline covering ADC (Antibody-Drug Conjugates) and IO (Immuno-Oncology) [3][10]. - The company has multiple oncology product pipelines, including immune therapy, ADC targeted therapy, and oncolytic virus drugs, with several candidates in clinical stages [3][11]. - The company achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development and sales [3][25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, establishing a comprehensive ADC technology platform and has developed multiple ADC products, including PD-1 monoclonal antibody and MRG003 [11][14]. - The pipeline includes six ADC drugs, one oncolytic virus, and one TCE (T-cell Engager) drug in clinical stages, with several candidates entering pivotal trials [14][18]. Unique Features of ADC Candidates - MRG003 (EGFR ADC) has been approved for NPC (Nasopharyngeal Carcinoma) in China, showing superior survival benefits and safety compared to competitors [4][30]. - MRG004A (TF-ADC) is in Phase III trials for pancreatic cancer, while MRG006A (GPC3 ADC) targets the liver cancer market and is expected to enter Phase III trials in 2026 [6][30]. Oncolytic Virus and International Expansion - The company introduced the oncolytic virus therapy CG0070, which is in critical registration trials in China and has shown promising efficacy in the U.S. for bladder cancer [5][30]. - The company has successfully partnered for international expansion with MRG007 (CDH17 ADC) and CTM012 (CD3/4-1BB/DLL3 tri-antibody) [5][30]. Financial Projections and Investment Recommendations - Revenue projections for 2025, 2026, and 2027 are estimated at 880 million, 1.02 billion, and 1.49 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [6][30]. - The company is still in the investment phase for innovative drug development, with projected net profits of -20 million, 10 million, and 280 million yuan for the same years [6][30].

Investment Rating - The report assigns a "Buy" rating for the company, Lepu Biopharma (2157.HK), marking its first coverage [1]. Core Insights - The company is entering a harvest period for new drug approvals, having established a comprehensive pipeline in oncology that includes immunotherapy, ADC (Antibody-Drug Conjugate) targeted therapy, and oncolytic virus drugs. The company has multiple ADC drugs and other therapies in clinical stages, with expectations for new drug approvals in the next 3-5 years [3][10]. - The ADC pipeline is characterized by unique features and competitive advantages in various indications, with MRG003 (EGFR ADC) already approved for NPC (nasopharyngeal carcinoma) in China and showing promising results in other indications [4][30]. - The introduction of oncolytic virus therapy CG0070 has shown potential in the bladder cancer market, with successful regulatory progress in the U.S. and ongoing clinical trials in China [5][30]. - Financially, the company has achieved its first profit and positive operating cash flow in the first half of 2025, with steady revenue growth driven by business development and sales [25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, with a pipeline that includes immunotherapy, ADCs, and oncolytic virus therapies. It has developed a robust ADC technology platform and has multiple products in various stages of clinical development [11][10]. - The pipeline includes 6 ADC drugs and 1 oncolytic virus therapy, with several candidates in pivotal clinical stages, indicating a well-structured development strategy [14][10]. Unique Features of ADCs - MRG003 has been approved for NPC and is in advanced trials for HNSCC (head and neck squamous cell carcinoma) and NSCLC (non-small cell lung cancer), showcasing its broad applicability and competitive edge [30][4]. - Other ADCs in development, such as MRG004A for pancreatic cancer and MRG006A for liver cancer, are also progressing well, with MRG004A entering pivotal trials [30][6]. Financial Performance and Projections - The company reported revenues of 4.66 billion yuan in the first half of 2025, a significant increase from 1.33 billion yuan in the same period of 2024. The net profit for the same period was 290 million yuan, marking a turnaround from a loss of 197 million yuan in the previous year [25][30]. - Revenue projections for 2025, 2026, and 2027 are estimated at 8.8 billion yuan, 10.2 billion yuan, and 14.9 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [30].

Core Viewpoint - Lepu Biopharma-B (02157) experienced a significant stock increase, rising over 6% in late trading, with a current price of HKD 5.64 and a trading volume of HKD 71.31 million [1] Group 1: Clinical Trial Developments - CG Oncology is set to announce the primary data from the PIVOT-006 Phase 3 clinical trial evaluating the monotherapy of cretostimogene for high-risk non-muscle invasive bladder cancer in the first half of 2026, which is nearly one year ahead of the original schedule due to a much faster-than-expected enrollment rate [1] - Lepu Biopharma holds the rights to CG0070 injection (Cretostimogene Grenadenorepvec) in Greater China and is actively advancing clinical progress domestically while CG Oncology achieves clinical breakthroughs abroad [1] Group 2: Product Synergy - Lepu Biopharma possesses an already marketed PD-1 antibody, Putilizumab, which can complement the treatment of NMIBC when combined with cretostimogene, potentially enhancing therapeutic efficacy [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Lepu Biopharma-B (02157), which rose over 6% and is currently trading at 5.64 HKD with a trading volume of 71.31 million HKD [1] - CG Oncology is expected to announce the primary data from the PIVOT-006 Phase 3 clinical trial for cretostimogene monotherapy in high-risk non-muscle invasive bladder cancer in the first half of 2026, which is nearly a year earlier than originally planned due to a faster-than-expected enrollment rate [1] - Lepu Biopharma has exclusive rights to CG0070 injection (Cretostimogene Grenadenorepvec) in Greater China and is actively advancing clinical progress domestically while CG Oncology achieves clinical breakthroughs abroad [1] Group 2 - Lepu Biopharma possesses an already marketed PD-1 antibody, Putili monoclonal antibody, which can complement the treatment of NMIBC (non-muscle invasive bladder cancer) to enhance efficacy through combination therapy [1]

Core Viewpoint - Enhertu (DS-8201) has evolved into a "complete entity" with the recent approval for first-line therapy in HER2+ breast cancer, marking significant progress from its initial approval as a third-line therapy in December 2019 to its current status [1][2] Group 1: Enhertu's Progression - Enhertu's journey includes approvals for HER2+ breast cancer in third-line therapy (December 2019), second-line therapy (January 2021), and now first-line therapy [2] - The first-line therapy approval is in combination with pertuzumab, with expectations for single-agent approval in the future [2] Group 2: Competitive Landscape - The HER2 ADC breast cancer market is approaching a critical phase, with companies like Rongchang Biopharma, Kelun-Biotech, and BaiLi Tianheng adopting various strategies to compete [3][6] - Rongchang Biopharma has focused on differentiated strategies, avoiding direct competition in breast cancer and targeting unmet clinical needs in other indications like gastric cancer [4][6] - Kelun-Biotech has actively pursued HER2+ breast cancer, achieving approval for its product A166 as the first domestic ADC for second-line therapy, leveraging a strategy of gradual advancement [7][9] Group 3: Strategic Approaches - BaiLi Tianheng aims to create a competitive product against Enhertu, with its T-Bren ADC targeting both HER2+ breast cancer and non-small cell lung cancer (NSCLC) [11][14] - HengRui Medicine adopts a multi-cancer strategy, focusing on various indications beyond breast cancer, with its SHR-A1811 ADC already approved for HER2-mutated NSCLC [16][17] Group 4: Differentiated Strategies - Lepu Biopharma's strategy centers on combining its ADC with PD-1 therapies, positioning its products as complementary rather than direct competitors [18][20] - In contrast, YingEn Biopharma has established a global strategy, securing a partnership with BioNTech for its DB-1303 ADC, focusing on unmet needs in endometrial cancer [22][24] Group 5: Future Outlook - The competitive landscape in the HER2 ADC market is intensifying, with companies employing diverse strategies to carve out their niches [26] - The future success in this sector may hinge on the depth of differentiated strategies and the ability to commercialize effectively, rather than solely on product efficacy [26]

Investment Rating - The report maintains a "Recommended" rating for the companies involved in the chromatography industry, particularly focusing on domestic innovation and market potential [57]. Core Insights - The chromatography industry is experiencing significant growth, driven by the increasing demand in the biopharmaceutical sector, which accounts for 80% of the chromatography medium applications [22][37]. - The global biopharmaceutical market is projected to grow from approximately $503 billion in 2023 to $892 billion by 2028, with a compound annual growth rate (CAGR) of 9.5%-12.5% [30]. - Domestic biopharmaceutical market growth is robust, with projections indicating an increase from ¥262.2 billion in 2018 to ¥534.8 billion in 2024, reflecting a CAGR of 12.61% [37]. Market Overview - The chromatography industry includes core consumables, instruments, and software services, with a complete product system that plays a crucial role in drug purification and analysis [15][16]. - The chromatography equipment market is expected to see significant growth, with the small molecule liquid chromatography system market projected to grow from $3.6 billion in 2021 to $7.7 billion by 2026, representing a CAGR of 16.7% [40]. - The chromatography medium market in China is expected to grow from ¥112 billion in 2023 to over ¥203 billion by 2026, with a CAGR of 21.92% [47]. Key Segments - **Innovative Drugs**: The report highlights the transition from generic to innovative drugs in China, with a focus on companies like BeiGene and Innovent Biologics, which are expected to lead in product pipelines and market share [9][57]. - **Medical Devices**: The report notes a recovery in the bidding for imaging devices and a growing market for home medical devices, driven by government subsidies [61]. - **IVD (In Vitro Diagnostics)**: The report emphasizes the acceleration of domestic replacement in the luminescence sector, with companies like Mindray and New Industries leading the charge [59][60]. Industry Trends - The report identifies a shift towards domestic production and innovation in the chromatography sector, with local companies making significant strides in filling the gaps left by international firms [53][56]. - The biopharmaceutical sector's increasing reliance on chromatography technology for drug development and production is expected to drive demand for high-quality chromatography products [22][37]. - The report also discusses the impact of national policies aimed at promoting domestic high-end scientific instruments, which are expected to further enhance the growth of the chromatography industry [53].

Core Viewpoint - Lepu Biopharma-B (02157) saw a significant increase in stock price, rising over 4% following the announcement of its drug MRG003 being considered for breakthrough therapy designation for treating recurrent or metastatic nasopharyngeal carcinoma [1] Group 1: Stock Performance - Lepu Biopharma-B's stock rose by 4.11%, reaching HKD 7.34, with a trading volume of HKD 30.16 million [1] Group 2: Drug Development - The drug MRG003, an EGFR-targeted ADC, is proposed for breakthrough therapy designation, aimed at patients who have failed previous treatments with platinum-based drugs and PD-1/PD-L1 inhibitors [1] - MRG003 is currently the leading EGFR ADC drug in global development, having previously received breakthrough therapy designation and priority review from CDE, as well as orphan drug status and fast track designation from the FDA [1] - The company initially submitted a marketing application for MRG003 for nasopharyngeal carcinoma in September 2024, but withdrew it to provide additional information, and has since resubmitted it in March of this year, now included in the priority review process for specific recurrent/metastatic nasopharyngeal carcinoma patients [1]

Core Viewpoint - Lepu Biopharma-B (02157) saw a significant stock increase of over 4%, currently trading at 7.34 HKD, with a transaction volume of 30.16 million HKD, following the announcement of its drug MRG003 being considered for breakthrough therapy designation [1] Group 1: Drug Development and Regulatory Status - MRG003, an EGFR-targeted ADC drug developed by Lepu Biopharma, is proposed for breakthrough therapy designation for treating recurrent or metastatic nasopharyngeal carcinoma in patients who have previously failed platinum-based and PD-1/PD-L1 inhibitor treatments [1] - MRG003 is currently the leading EGFR ADC drug in global development, having previously received breakthrough therapy designation and priority review qualification from CDE, as well as orphan drug status, fast track designation, and breakthrough therapy designation from the FDA [1] - The company initially submitted the marketing application for MRG003 for nasopharyngeal carcinoma in September 2024 but withdrew it to provide additional information, and resubmitted it in March of this year, now included in the priority review process for specific recurrent/metastatic nasopharyngeal carcinoma patients [1]